Related Experiment Video

Updated: Apr 25, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a

Nabiha Faisal1, Eric M Yoshida2, Marc Bilodeau3

  • 1Toronto General Hospital, University of Toronto. Ontario, Canada.

Annals of Hepatology
|August 26, 2014
PubMed

Insights

Protease inhibitor (PI)-based triple therapy for Hepatitis C Virus (HCV) recurrence after liver transplantation showed improved viral clearance. However, tolerability and drug interactions require careful management.

Area of Science:

  • Hepatology
  • Virology
  • Transplantation Medicine

Background:

  • Hepatitis C Virus (HCV) remains a primary reason for liver transplantation (LT).
  • Standard therapies for recurrent HCV in Genotype 1 (G1) LT recipients yield low sustained virological response (SVR) rates.
  • Limited data exists on triple therapy with protease inhibitors (PIs) for this population.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of boceprevir (BOC) and telaprevir (TVR)-based triple therapies for recurrent G1 HCV in liver transplant recipients.
  • To assess drug-drug interactions with immunosuppressants like cyclosporine and tacrolimus.

Main Methods:

  • A national multicenter retrospective study included 76 patients with G1 HCV recurrence post-LT.
  • Patients received either BOC (n=41) or TVR (n=35) triple therapy.
  • Immunosuppression regimens included cyclosporine, tacrolimus, or prednisone.

Main Results:

  • On-treatment virologic response was high (84%), with similar rates for BOC and TVR.
  • Rapid virologic response (RVR) at week 4 was significantly higher with TVR (81%) vs. BOC (63%).
  • SVR 12 weeks post-treatment was 59.5% overall; anemia was common (72%), and serious adverse effects led to early discontinuation in 23 patients. Significant dose reductions of immunosuppressants were required.

Conclusions:

  • PI-based triple therapy demonstrates increased HCV-RNA clearance compared to dual therapy.
  • Tolerability is a significant concern, necessitating close monitoring for adverse events and drug-drug interactions.
  • Management of immunosuppressant drug levels is crucial for safety during PI-based therapy.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.7K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
55
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
18
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
625